Treatment of autism models with highly selective inhibitors of the H3K4me2 demethylase LSD1 results in a robust rescue of the core symptoms of ASD, revealing an important role of H3K4me2 abnormality in ASD pathophysiology and the therapeutic potential of targeting H3K4me2 demethylase LSD1 (Rapanelli et al., 2022). Here, KDM1A is linked to autism.